Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

How to Choose a Good Investment Plan in India

Choosing the right investment plan is crucial to helping you achieve your life goals. Whether you want to save for your child's education, plan for your retirement, or buy a home, your investment options should align with your goal. There are numerous types of investment options available in India, which can be pretty overwhelming, especially if you are just getting started. But once you understand your objectives and the options available to you, you can make decisions with increased confidence.
How to Choose a Good Investment Plan in India

Step 1: Know Your Financial Goals

Before selecting an investment, take a moment to consider your goals. You can divide them into three types:

  • Short-term goals: These are things you want to do in the next 1 to 3 years, such as travel or build an emergency fund.
  • Medium-term goals: These include plans like buying a car or paying for school fees within 3 to 7 years.
  • Long-term goals: These can be retirement savings or your child’s higher education, usually planned for after 7 years.

Each goal type needs a different kind of investment. For example, long-term goals may need equity-linked options. Short-term goals are better suited to safe and stable investments.

Step 2: Understand How Much Risk You Can Take

Some investments carry more risk than others. If you are young and have a steady income, you might be comfortable with higher-risk investments. If you are older or have many responsibilities, you may prefer safer options.

Here is a simple table to help:

Risk LevelSuitable Investments
HighEquity mutual funds, direct stocks, ULIPs
MediumBalanced funds, a mix of debt and equity
LowPPF, fixed deposits, guaranteed return plans

Knowing your risk level helps you avoid losses and choose better options.

Step 3: Think About How Long You Want to Invest

The length of time you plan to stay invested is referred to as your investment horizon. This will help you decide where to put your money.

If you need the money soon, consider safe and liquid options, such as fixed deposits.

If you can wait for several years, you may be able to invest in equity funds or other market-linked options.

For example, if you are saving for your child’s college education 15 years from now, you could look at a unit-linked insurance plan (ULIP). It offers both life cover and investment growth over time.

Step 4: Match Your Goals with the Right Investment

India offers many investment tools. The right one depends on what you need.

For Building Wealth:

  • Equity mutual funds offer good growth over time but involve market risk.
  • ULIPs allow you to invest while also providing life insurance.
  • NPS is a good option if you are planning for retirement.

For Safety and Regular Income:

  • PPF is backed by the government and gives steady, tax-free returns.
  • Fixed deposits are good for people who want guaranteed returns.
  • Monthly income schemes are beneficial for individuals who require regular payments.

For Saving Tax:

  • ELSS helps you save tax while growing your money simultaneously.
  • ULIPs can also help you reduce taxable income under the old tax regime.

If you are exploring Best investment options in India, consider using a mix of tools. This way, you can reduce risk and still work toward your goals.

Step 5: Make Sure You Can Access Your Money When Needed

Some investments lock your money for a fixed time. Others let you take it out early if needed. Think about how easy it is to get your money back in case of an emergency.

  • Fixed deposits can be closed early, but a penalty may be incurred.
  • Mutual funds allow withdrawals unless they are subject to a lock-in period, such as ELSS.
  • PPF has limits on early withdrawal.
  • ULIPs typically have a 5-year lock-in period.

Keep part of your money in places where you can easily access it, especially if your goals are likely to change.

Step 6: Include Life Insurance in Your Plan

A good financial plan includes protection. Life insurance ensures that your family will not face financial trouble if something happens to you. It is a basic need before you start investing in other things.

Plans from Axis Max Life Insurance, like ULIPs, combine insurance and investment. They can be helpful for long-term goals, such as a child’s education or retirement planning.

Step 7: Look at the Costs and Tax Benefits

Different investments have different costs. These charges can reduce your earnings if you do not plan properly.

  • Mutual funds may have fund management charges or exit fees.
  • ULIPs can include several charges, such as policy fees and fund charges.
  • Fixed deposits offer steady returns, but the interest may be taxable.
  • PPF offers tax-free interest but has a long lock-in period.
  • Tax advantages can depend on the tax framework you decide to follow.

Note: Tax deduction under Section 80C is available only under the old tax regime. If you intend to invest in any tax-saving asset tools, you should consult with a tax professional beforehand.

You should always check how much money you’ll actually make after taxes and charges when making your investment selection.

Step 8: Frequently Review Your Investment Plan

Your goals may change as your life changes. It is good to simply check on your investments a couple of times every year.

If your income has increased, you may want to consider investing more. If you are nearing your goal, you should change from riskier options to safer ones. A regular review of your plan gives you a better chance at keeping your targets on track.

Conclusion

There is no single answer to finding the right investment, and choosing a plan that works best for you should take into account your goals, income, and the time you have available to complete your investment. It should also match how much risk you are comfortable with.

Mixing different types of investments can give you better results. For example, you might use mutual funds to grow your money, a PPF account for safety, and insurance for protection. All of these work together to create a stronger financial future.

Take your time to evaluate your options. Decide what makes sense for your life today and for the life that you want tomorrow. Be consistent, check your progress regularly, and modify your plan as necessary. That is the better way to head toward financial security.

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi